Prurigo clinical trials
The registry lists 29 studies for Prurigo across more than 10 countries. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-03.
Status
- Completed
- 17
- Status unknown
- 5
- Not yet recruiting
- 3
- Recruiting
- 2
- Withdrawn
- 1
- Terminated
- 1
Phase
- Phase 3
- 12
- Phase 2
- 11
- Phase 1
- 2
- Phase 4
- 1
Where
- United States
- 14
- Germany
- 14
- Poland
- 10
- Austria
- 7
- France
- 5
- China
- 4
Who runs them
Galderma R&D (4) · Vyne Therapeutics Inc. (4) · Incyte Corporation (2) · Trevi Therapeutics (2) · Second Affiliated Hospital, School of Medicine, Zhejiang University (2) · Hadassah Medical Organization (1) · University of Maryland, Baltimore (1) · Tanja Todberg, MD (1)
Studies
Recruiting first, then most recently updated. Showing 29 of 29 — search for more.
- Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis PatientsNot yet recruitingNCT07620561Phase 21 country
- Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo NodularisRecruitingNCT06779136Phase 31 country
- China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment ProjectRecruitingNCT053168051 country
- A Randomized, Double-blinded, Self-controlled Clinical Study of Intralesional Injection of 5-fluorouracil Plus Triamcinolone for the Treatment of Refractory Nodular PrurigoNot yet recruitingNCT06524323Phase 31 country
- Efficacy and Safety of Tofacitinib in Patients With Prurigo NodularisNot yet recruitingNCT06201715Not applicable1 country
- A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)CompletedNCT05755438Phase 311 countries
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)CompletedNCT05764161Phase 313 countries
- Study of Nalbuphine HCl ER Tablets in Patients With Prurigo NodularisCompletedNCT02174419Phase 2/33 countries
- Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo NodularisCompletedNCT02174432Phase 2/31 country
- Topical Aprepitant in Prurigo PatientsCompletedNCT01963793Phase 21 country
- A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo NodularisCompletedNCT05052983Phase 37 countries
- Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)CompletedNCT04501666Phase 310 countries
- A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)CompletedNCT04501679Phase 39 countries
- Benralizumab in Chronic Prurigo - Investigating Clinical Efficacy (BICPIC)WithdrawnNCT05528913Phase 21 country
- A Study of CDX-0159 in Patients With Prurigo NodularisCompletedNCT04944862Phase 13 countries
- Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown OriginCompletedNCT05038982Phase 21 country
- Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo NodularisCompletedNCT03677401Phase 33 countries
- A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)CompletedNCT02196324Phase 21 country
- Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)TerminatedNCT03540160Phase 34 countries
- Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo NodularisCompletedNCT03546816Phase 31 country
- Pain Outcomes Following Intralesional Corticosteroid InjectionsCompletedNCT03630198Phase 41 country
- Transcriptomic Landscape of T Lymphocytes of Atopic Dermatitis, Atopic Prurigo Nodularis (of Besnier) and Non-atopic Prurigo Nodularis (of Hyde) Using Single Cell RNA-sequencingStatus unknownNCT04681300
- Safety and Efficacy of Nemolizumab in PNCompletedNCT03181503Phase 24 countries
- Apremilast as Anti-pruritic Treatment in Patients With Prurigo NodularisStatus unknownNCT03576287Phase 1/21 country
- Mechanisms of Action of Photo(Chemo)Therapy in Skin DiseasesStatus unknownNCT03340155Not applicable1 country
- Safety and Efficacy of CC-10004 for Prurigo NodularisCompletedNCT00869089Phase 21 country
- Dapsone Prurigo StudyStatus unknownNCT01870050Not applicable1 country
- Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic DiseaseCompletedNCT00507832Phase 21 country
- Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo NodularisStatus unknownNCT00532519Not applicable1 country